Related references
Note: Only part of the references are listed.MHC-I genotype and tumor mutational burden predict response to immunotherapy
Aaron M. Goodman et al.
GENOME MEDICINE (2020)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Rachel Marty et al.
CELL (2018)
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Samuel F. Bakhoum et al.
CELL (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Rachel Marty et al.
CELL (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ABO blood type correlates with survival on prostate cancer vaccine therapy
Saddam M. Muthana et al.
ONCOTARGET (2015)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)
Ludger Klein et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
